Medgenics Inc Notice of Allowance for Claims that Expand IP (8846C)
22 Abril 2013 - 8:15AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 8846C
Medgenics Inc
22 April 2013
Press Release 22 April 2013
Medgenics Receives Notice of Allowance from the U.S. Patent
Office for Claims That Expand IP for Its Platform Technology to
Additional Therapeutic Proteins
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG)(the
"Company"), the developer of Biopump(TM), a novel technology for
the sustained production and delivery of therapeutic proteins in
patients using their own tissue, today announced the United States
Patent and Trademark Office has issued a Notice of Allowance of
claims that expand the Company's scope of patent coverage for
additional therapeutic proteins.
The claims in the patent are directed to a dermal Biopump
expressing at least one recombinant gene product from any of the
following: growth hormone, interferon beta, insulin, PDGF-BB,
interleukin-1 receptor agonist (IL-1Ra), peptide YY3-36,
interleukin-10 (IL-10) and G-CSF. These claims, combined with the
prior grant of patents for genetically modified dermal micro-organ
expression of erythropoietin and interferon alpha, broaden
Medgenics' scope of intellectual property in the field of
genetically modified dermal micro-organs.
Upon the issuance of this patent, Medgenics' global patent
portfolio will include 45 patents granted, with 79 patent
applications pending.
Medgenics believes its approach to protein therapy will have
multiple benefits compared with current treatments, which include
regular and costly injections of therapeutic proteins. Medgenics'
technologies target a range of clinical indications within the
global protein therapy market, which is forecast to reach $143
billion in 2015.
"With this allowance we have further broadened the universe of
therapeutic proteins that can be delivered through our Biopump
platform technology. We continue to build the value of our
intellectual property worldwide with the knowledge that new
therapeutic areas will be covered by our patent portfolio," stated
Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of
Medgenics.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis and hemophilia, among others.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Source: Medgenics, Inc.
- Ends -
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
Andrew.pearlman@medgenics.com
LHA Phone: +1 212-838-3777
Anne Marie Fields
afields@lhai.com
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
Jamie.hooper@abchurch-group.com
Nomura Code Securities (NOMAD & Joint Phone: +44 207 776 1200
Broker)
Jonathan Senior
Giles Balleny
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Brearley
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUCPCUPWUBP
Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024